 Epirubicin cardiotoxicity study patients advanced breast cancer cardiotoxicity epirubicin EPI ECG multiple ECG-gated radionuclide determination left ventricular ejection fraction LVEF rest patients advanced breast cancer EPI doses days weeks vindesine schedule median cumulative dose EPI range patients congestive heart failure CHF patients EPI none CHF patients doses CHF confidence limits patients EPI CHF confidence limits patients due cardiotoxicity risk EPI cardiotoxicity present schedule considerable doses doses risk CHF decreases doses negligible patients prevalence CHF sensitivity LVEF high due low incidence CHF patients EPI prevalence CHF sensitivity specificity results LVEF value predictor CHF